Meme kanserinde PRAME (preferentially expressed antigen of melanoma) ekspresyonunun prognostik önemi

Year 2020, Volume: 45 Issue: 3, 1202 - 1209, 30.09.2020

Kubilay Dalcı , Yalçın Kekeç Semra Paydaş , Suzan Zorludemir Melek Ergin Kahraman Tanrıverdi , Gülşah Seydaoğlu , Gülsüm Uçar

https://doi.org/10.17826/cumj.723828

Abstract

Amaç: Bu çalışmanın amacı 54 meme kanseri ve 37 iyi huylu meme lezyonu olan hastada PRAME (Preferentially Expressed Antigen of Melanoma) ekspresyonunu tespit etmektir.
Gereç ve Yöntem: Reverse transkripsiyon polimeraz zincir reaksiyonu (RT-PCR) ile 54 meme kanseri, 20 benign meme lezyonu ve 10 normal meme dokusu örneğindeki PRAM Eekspresyonu çalışıldı. İmmunohistokimyasal (IHC) yöntem ile PRAME ekspresyonu, 54 meme kanserili hastanın hem tümör hem de normal meme dokusundan ve 37 benign meme lezyonunda çalışıldı. PRAME için RT-PCR ve IHC sonuçları bu çalışmada karşılaştırıldı.
Bulgular: Meme kanserinin %50'sinde, benign meme lezyonlarının ise %25'inde PRAME ekspresyonu olduğu saptandı. İnvaziv meme kanseri olan dokularda IHC yöntemi kullanılarak bakılan PRAME ekspresyonunda; (+), (++) ve (+++) boyanma oranları sırasıyla %29,6, %31,5 ve %3,7 oranında bulundu. Hem IHC hem de RT-PCR ile saptanan PRAME ekspresyonu prognostik parametrelerle karşılaştırıldı. Meme kanserinde PRAME ekspresyonunun yüksek grade ve negatif hormon reseptörü ile ilişkili olduğu tespit edildi. RT-PCR ile IHC ile bakılan PRAME sonuçları arasında anlamlı ilişki bulundu.
Sonuç: Hem taze dokularda RT-PCR yöntemi, hem de parafin bloklarda IHC yöntemi, meme kanserinde PRAME ekspresyonunu ve PRAME’in prediktif önemini belirlemede kullanılabilir.

Keywords

Meme kanseri, , PRAME, Prognostik faktörler, Prediktif faktörler, RT-PCR, İHK, , İmmünoterapi, , Testis-kanser antijeni

Supporting Institution

Çukurova Üniversitesi Bilimsel Araştırma Projeleri Birimi

Prognostic significance of PRAME (preferentially expressed antigen of melanoma) expression in breast cancer

Abstract

Purpose: The aim of this study is to detect the PRAME (Preferentially Expressed Antigen of Melanoma) in 54 patients with breast cancer and 37 patients with benign breast lesions.
Materials and Methods: PRAME expressions in 54 breast cancer, 20 benign breast lesions and 10 normal breast tissue samples were studied with RT-PCR. Expression of PRAME was studied with IHC in 37 benign breast lesions, in 54 breast cancer patients from both tumor and normal breast tissue. RT-PCR and IHC results for PRAME were compared in this study.
Results: PRAME was found to be expressed in 50 % of the breast cancer and 25 % of the benign breast lesions. Using IHC method, (+), (++) and (+++) staining for PRAME expression were found in 29,6%, 31,5% and 3,7% of the cases, respectively in invasive component of the breast cancer. PRAME expression detected by both IHC and RT-PCR was compared with prognostic parameters. PRAME expression in breast cancer was found to be associated with high tumor grade and negative hormone receptor. We found an important association between PRAME RT-PCR and of PRAME IHC.
Conclusion: Both RT-PCR in fresh tissues and IHC method in paraffin embedded tissues can be used to identify PRAME expression and the predictive role of PRAME expression.

Keywords

breast cancer, PRAME, expression

References

• 1. Ikeda H, Lethe B, Lehmann F. Characterization of an antigennthat is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997;6:199-208.
• 2. Li CM, Guo M,Borczuk A. Gene expression in Wilm’s tumour mimics the earliest committed evre in the metanephric mesenchymal-epithelial transition. AM J Pathol, 2002;160:2181-2190.
• 3. Paydas S, Tanrıverdi K, Yavuz S, Seydaoğlu G. PRAME mRNA levels in cases with chronic leukemia: clanical importance and review of the literature. Leuk Res, 2007;31:365-9.
• 4. Paydas S, Tanriverdi K, Yavuz S, Disel U, Baslamisli F, Burgut R. PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects. J. Hematol. 79; 257-261, 2005. 5. Neumann E,Engelsberg A, Decker J. Heterogeneous expression of the tumour -associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell -based immunotherapies? Cancer Res, 2006;58;4090-4095
• 6. Matsushita M, Yamazaki R, Kawakami Y. Quantitative analysis of PRAME for detection of minimal residual disease in leukaemia. Methods Mol Med, 2004;97:267-275.
• 7. Oberthuer A, Hero B, Spitz R, Berthold F, Fischer M. The tumour-associated antigen PRAME is universally expressed in high-evre neuroblastoma and associated with poor outcome. Clin Cancer Res, 2004;10:4307-4313
• 8. Epping MT, Wang L, Edel MJ, Carlee L, Hernandez M, Bernards R. The human tumour antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell, 2005;122:835-847
• 9. Epping MT, Bernards R. A causal role for the human tumour antigen preferentially expressed antigen of melanoma in cancer. Cancer Res, 2006;66:10639-10642
• 10. Tajeddine N, Gala JL, Louis M. Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspaseindependent cell death in vitro and reduces tumorigenicity in vivo. Cancer Res, 2005;65:7348-55.
• 11. Gollner S, Steinbach D, Schenk T, Gruhn B,Zintl F, Ramsay E. Childhood acute myelogenous leukamia: association between PRAME, apoptosis and MDR- reletad gene expression. Eur J Cancer 2006;42:2807-14.
• 12. Santamaría C, Chillón MC, García-Sanz R, Balanzategui A, Sarasquete ME, Alcoceba M, Ramos F, Bernal T, Queizán JA, Peñarrubia MJ, Giraldo P, San Miguel JF, Gonzalez M. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia. Haematologica. 2008; 93: 1797-1805. 13. Doolan P, Clynes M, Kennedy S, Mehta JP, Crown J, O’Driscoll L. Prevalence and prognostic and predictive relevance of PRAMEin breast cancer. Breast Cancer Res Treat July 12, 2007.
• 14. Epping MT, Hart AA, Glas AM, Krijgsman O, Bernards R. PRAME expression and clinical outcome of breast cancer. Br J Cancer, 2008;99 (3):398-403.
• 15. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the Cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18:581-92.
• 16. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer Statistics, 2007. CA Cancer J Clin 2007;57;43-66.
• 17.Henderson IC. Prognostic factors. In: Haris JR, Helman S, Henderson IC, Kine DW, editors. Breast diseases. JB lippincott CO, 2th edition 1991: 332-46.
• 18. Matsushita M, Ikeda H, Kizaki M. Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia. Br J Haematol 2001;112:916-26